MX2016006049A - Mimeticos de calcitonina para tratar enfermedades y trastornos. - Google Patents
Mimeticos de calcitonina para tratar enfermedades y trastornos.Info
- Publication number
- MX2016006049A MX2016006049A MX2016006049A MX2016006049A MX2016006049A MX 2016006049 A MX2016006049 A MX 2016006049A MX 2016006049 A MX2016006049 A MX 2016006049A MX 2016006049 A MX2016006049 A MX 2016006049A MX 2016006049 A MX2016006049 A MX 2016006049A
- Authority
- MX
- Mexico
- Prior art keywords
- poorly regulated
- seq
- amino acid
- terminal end
- type
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/585—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Péptidos miméticos de calcitonina que tienen una secuencia de aminoácidos de acuerdo con SEQ ID NO: 8 o SEQ ID NO: 53, cada una de las cuales puede ser carboxilada en su extremo N-terminal o de otra manera modificada para reducir la carga positiva del primer aminoácido e independientemente de eso puede ser amidada en su extremo C-terminal, y en cada una de las cuales los residuos de cisteína en la posición 1 y 7 juntos pueden ser sustituidos por un ácido a-aminosubérico (Asu) son útiles como medicamentos para tratar la diabetes (Tipo I y/o tipo II), el exceso de peso corporal, el consumo excesivo de alimentos, síndrome metabólico, artritis reumatoide, enfermedad de hígado graso no alcohólico, la osteoporosis o la osteoartritis, niveles de glucosa en sangre pobremente regulados, respuesta mal regulada en pruebas de tolerancia a la glucosa o ingesta de alimentos mal regulada.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201320112A GB201320112D0 (en) | 2013-11-14 | 2013-11-14 | Calcitonin Mimetics for treating diseases and disorders |
| GB201414706A GB201414706D0 (en) | 2014-08-19 | 2014-08-19 | Calcitonin mimetics for treating diseases and disorders |
| PCT/EP2014/074207 WO2015071229A1 (en) | 2013-11-14 | 2014-11-10 | Calcitonin mimetics for treating diseases and disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016006049A true MX2016006049A (es) | 2016-08-12 |
| MX373251B MX373251B (es) | 2020-05-04 |
Family
ID=51947308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016006049A MX373251B (es) | 2013-11-14 | 2014-11-10 | Miméticos de calcitonina para tratar enfermedades y trastornos. |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10232021B2 (es) |
| EP (3) | EP3321278B1 (es) |
| JP (1) | JP6639389B2 (es) |
| KR (1) | KR20160075794A (es) |
| CN (1) | CN105722854B (es) |
| AU (2) | AU2014350328B2 (es) |
| BR (1) | BR112016010643A2 (es) |
| CA (1) | CA2928654A1 (es) |
| CY (2) | CY1119976T1 (es) |
| DK (2) | DK3321278T3 (es) |
| ES (2) | ES2660788T3 (es) |
| HR (2) | HRP20180337T1 (es) |
| HU (2) | HUE044465T2 (es) |
| LT (2) | LT3321278T (es) |
| MX (1) | MX373251B (es) |
| NO (1) | NO3068796T3 (es) |
| PH (1) | PH12016500705B1 (es) |
| PL (2) | PL3321278T3 (es) |
| PT (2) | PT3321278T (es) |
| RS (2) | RS58530B1 (es) |
| RU (1) | RU2689551C1 (es) |
| SI (2) | SI3068796T1 (es) |
| TR (1) | TR201802765T4 (es) |
| WO (1) | WO2015071229A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201500263D0 (en) * | 2015-01-08 | 2015-02-25 | Keybioscience Ag | Calcitonin analogues for treating diseases and disorders |
| KR101869595B1 (ko) | 2016-06-08 | 2018-06-21 | 부경대학교 산학협력단 | 성게 유래 칼시토닌 유사 펩타이드를 유효성분으로 포함하는 골 질환 예방 또는 치료용 조성물 |
| CN108424460A (zh) * | 2017-02-13 | 2018-08-21 | 成都贝爱特生物科技有限公司 | GLP-1类似物和davalintide类似物的融合蛋白制备及其用途 |
| CN106880835A (zh) * | 2017-02-17 | 2017-06-23 | 云南同方科技有限公司 | 用于缓解高血压症状的植物精油复合物制备及应用 |
| GB201704429D0 (en) | 2017-03-21 | 2017-05-03 | Keybioscience Ag | Calcitonin mimetics for treating diseases and disorders |
| GB201707955D0 (en) | 2017-05-18 | 2017-07-05 | Keybioscience Ag | Dual amylin and calcitonin receptor agonists for treating diseases and disorders |
| GB201813678D0 (en) | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Acylated calcitonin mimetics |
| GB201813677D0 (en) | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Calcitonin mimetics for treating diseases and disorders |
| JOP20220110A1 (ar) | 2019-11-11 | 2023-01-30 | Boehringer Ingelheim Int | ناهضات مستقبل npy2 |
| MX2023001532A (es) | 2020-08-07 | 2023-03-08 | Boehringer Ingelheim Int | Agonistas del receptor npy2 solubles. |
| TWI901926B (zh) | 2020-12-18 | 2025-10-21 | 美商美國禮來大藥廠 | 雙重澱粉素及降鈣素受體促效劑及其用途 |
| WO2024050289A1 (en) | 2022-08-29 | 2024-03-07 | Eli Lilly And Company | Compositions for oral delivery |
| WO2025240893A1 (en) | 2024-05-17 | 2025-11-20 | Eli Lilly And Company | 4-phenyl-1h-pyrazolo[3,4-b]pyridine-5-carboxamide derivatives as amylin and/or calcitonin receptor agonists for the treatment of type 2 diabetes, obesity or overweight |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4708934A (en) | 1984-09-27 | 1987-11-24 | Unigene Laboratories, Inc. | α-amidation enzyme |
| US6319685B1 (en) | 1984-09-27 | 2001-11-20 | Unigene Laboratories, Inc. | Alpha-amidating enzyme compositions and processes for their production and use |
| US5789234A (en) | 1987-08-14 | 1998-08-04 | Unigene Laboratories, Inc. | Expression systems for amidating enzyme |
| JPH03240797A (ja) * | 1990-02-15 | 1991-10-28 | Sagami Chem Res Center | 新規カルシトニン誘導体 |
| US5102666A (en) | 1990-09-11 | 1992-04-07 | Oramed, Inc. | Calcium polycarbophil controlled release composition and method |
| JPH04149198A (ja) * | 1990-10-12 | 1992-05-22 | Sagami Chem Res Center | カルシトニン誘導体 |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US6692766B1 (en) | 1994-06-15 | 2004-02-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Controlled release oral drug delivery system |
| US5866536A (en) | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
| US5773647A (en) | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| EP2088188B1 (en) | 1997-04-16 | 2011-08-31 | Unigene Laboratories, Inc. | Direct expression of peptides into culture media |
| DE19736457C2 (de) * | 1997-08-21 | 2001-08-23 | Fraunhofer Ges Forschung | Calcitonin-Derivate mit einer Verbrückung zwischen den Aminosäuren an den Positionen 17 und 21 |
| CN1329502A (zh) | 1998-12-04 | 2002-01-02 | 普罗瓦利斯英国有限公司 | 含有胰岛素的药物组合物 |
| CA2369591C (en) | 1999-04-05 | 2011-06-14 | Emisphere Technologies, Inc. | Disodium salts, monohydrate, and ethanol solvates |
| US6780846B1 (en) | 1999-09-27 | 2004-08-24 | Elan Corporation, Plc | Membrane translocating peptide drug delivery system |
| GB2368792A (en) | 2000-10-06 | 2002-05-15 | Roger Randal Charles New | Absorption enhancers |
| US6673574B2 (en) | 2000-11-30 | 2004-01-06 | Unigene Laboratories Inc. | Oral delivery of peptides using enzyme-cleavable membrane translocators |
| US7316819B2 (en) | 2001-03-08 | 2008-01-08 | Unigene Laboratories, Inc. | Oral peptide pharmaceutical dosage form and method of production |
| US6770625B2 (en) | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
| EP2359817B1 (en) | 2003-03-28 | 2018-01-10 | Sigmoid Pharma Limited | Solid oral dosage form containing seamless microcapsules |
| GB0308732D0 (en) | 2003-04-15 | 2003-05-21 | Axcess Ltd | Absorption enhancers |
| WO2005014031A1 (en) | 2003-07-23 | 2005-02-17 | Novartis Ag | Use of calcitonin in osteoarthritis |
| AU2004317954A1 (en) | 2003-09-17 | 2005-10-13 | Chiasma, Inc. | Compositions capable of facilitating penetration across a biological barrier |
| US20080200563A1 (en) | 2004-07-22 | 2008-08-21 | Thiomatrix Forschungs- Und Beratungs- Gmbh | Use of Compounds Containing Thiol Groups as Efflux Pump Inhibitors |
| US7445911B2 (en) | 2004-11-24 | 2008-11-04 | Unigene Laboratories Inc. | Enzymatic reactions in the presence of keto acids |
| US8815583B2 (en) | 2005-06-24 | 2014-08-26 | Enteris Biopharma, Inc. | Cell lines for expressing enzyme useful in the preparation of amidated products |
| JP5222727B2 (ja) | 2005-09-06 | 2013-06-26 | オーラメッド・ファーマスーティカルズ・インコーポレイテッド | タンパク質を経口投与するための方法及び組成物 |
| US8093207B2 (en) | 2005-12-09 | 2012-01-10 | Unigene Laboratories, Inc. | Fast-acting oral peptide pharmaceutical products |
| PT1834635E (pt) | 2006-03-13 | 2011-10-13 | Advanced In Vitro Cell Technologies S L | Sistemas estáveis de nanocápsula para a administração de moléculas activas |
| ES2426445T3 (es) | 2006-04-07 | 2013-10-23 | Merrion Research Iii Limited | Forma de dosificación oral sólida que contiene un potenciador |
| US8377863B2 (en) | 2007-05-29 | 2013-02-19 | Unigene Laboratories Inc. | Peptide pharmaceutical for oral delivery |
| US8962015B2 (en) | 2007-09-28 | 2015-02-24 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
| AU2012328699B2 (en) * | 2011-10-25 | 2016-03-31 | VMware LLC | Network virtualization apparatus and method with scheduling capabilities |
| US9006172B2 (en) | 2011-11-02 | 2015-04-14 | Keybioscience Ag | Peptide analogs for treating diseases and disorders |
-
2014
- 2014-11-10 BR BR112016010643A patent/BR112016010643A2/pt active Search and Examination
- 2014-11-10 MX MX2016006049A patent/MX373251B/es active IP Right Grant
- 2014-11-10 PL PL17208140T patent/PL3321278T3/pl unknown
- 2014-11-10 JP JP2016530131A patent/JP6639389B2/ja not_active Expired - Fee Related
- 2014-11-10 PT PT17208140T patent/PT3321278T/pt unknown
- 2014-11-10 US US15/036,475 patent/US10232021B2/en not_active Expired - Fee Related
- 2014-11-10 ES ES14802345.0T patent/ES2660788T3/es active Active
- 2014-11-10 PL PL14802345T patent/PL3068796T3/pl unknown
- 2014-11-10 PT PT148023450T patent/PT3068796T/pt unknown
- 2014-11-10 AU AU2014350328A patent/AU2014350328B2/en not_active Ceased
- 2014-11-10 SI SI201430612T patent/SI3068796T1/en unknown
- 2014-11-10 CA CA2928654A patent/CA2928654A1/en not_active Abandoned
- 2014-11-10 EP EP17208140.8A patent/EP3321278B1/en active Active
- 2014-11-10 LT LTEP17208140.8T patent/LT3321278T/lt unknown
- 2014-11-10 HU HUE17208140 patent/HUE044465T2/hu unknown
- 2014-11-10 ES ES17208140T patent/ES2713851T3/es active Active
- 2014-11-10 RS RS20190279A patent/RS58530B1/sr unknown
- 2014-11-10 DK DK17208140.8T patent/DK3321278T3/en active
- 2014-11-10 RS RS20180244A patent/RS57152B1/sr unknown
- 2014-11-10 CN CN201480062032.2A patent/CN105722854B/zh not_active Expired - Fee Related
- 2014-11-10 LT LTEP14802345.0T patent/LT3068796T/lt unknown
- 2014-11-10 HR HRP20180337TT patent/HRP20180337T1/hr unknown
- 2014-11-10 NO NO14802345A patent/NO3068796T3/no unknown
- 2014-11-10 WO PCT/EP2014/074207 patent/WO2015071229A1/en not_active Ceased
- 2014-11-10 SI SI201431101T patent/SI3321278T1/sl unknown
- 2014-11-10 KR KR1020167015410A patent/KR20160075794A/ko not_active Abandoned
- 2014-11-10 RU RU2016123180A patent/RU2689551C1/ru active
- 2014-11-10 TR TR2018/02765T patent/TR201802765T4/tr unknown
- 2014-11-10 EP EP18208763.5A patent/EP3470422A1/en not_active Withdrawn
- 2014-11-10 EP EP14802345.0A patent/EP3068796B1/en active Active
- 2014-11-10 HU HUE14802345A patent/HUE037663T2/hu unknown
- 2014-11-10 DK DK14802345.0T patent/DK3068796T3/en active
-
2016
- 2016-04-15 PH PH12016500705A patent/PH12016500705B1/en unknown
-
2018
- 2018-02-28 CY CY20181100253T patent/CY1119976T1/el unknown
- 2018-04-09 AU AU2018202480A patent/AU2018202480A1/en not_active Abandoned
-
2019
- 2019-01-21 US US16/252,780 patent/US20190142903A1/en not_active Abandoned
- 2019-02-25 HR HRP20190356TT patent/HRP20190356T1/hr unknown
- 2019-02-28 CY CY20191100252T patent/CY1121332T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016006049A (es) | Mimeticos de calcitonina para tratar enfermedades y trastornos. | |
| EA201690494A1 (ru) | Ацилированные аналоги глюкагона | |
| CY1122539T1 (el) | Αναλογα γλυκαγονης | |
| CO7400885A2 (es) | Análogos de glucagón | |
| PE20151808A1 (es) | Peptidos terapeuticos | |
| CL2017000201A1 (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
| PE20141727A1 (es) | Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas | |
| EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
| BR112014012808A2 (pt) | proteína de fusão anticâncer | |
| CR20180378A (es) | Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agosnistas de glp-1 | |
| PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
| AR091422A1 (es) | Analogos peptidicos de la exendina 4 | |
| EA201590525A1 (ru) | Слитые белки для лечения метаболического синдрома | |
| BR112019011144A2 (pt) | compostos como agonistas peptídicos de receptor de glp1/glucagon/gip | |
| PE20121726A1 (es) | Emulsiones nutricionales que comprenden beta-hidroxi-beta-metilbutirato (hmb) de calcio y proteina soluble | |
| UY35740A (es) | Análogos de amilina | |
| BR112014012460A2 (pt) | proteínas recombinantes e seus usos terapêuticos | |
| BR112017014580A8 (pt) | Método para obter um isolado peptídico a partir de uma biomassa de microalgas enriquecidas com proteína | |
| BR112015018265A2 (pt) | Composições nutricionais contendo um componente peptídico com propriedades estimulantes de adiponectina e utilizações das mesmas | |
| BR112016002572A2 (pt) | peptídeos | |
| BR112018010155A8 (pt) | segmentação do receptor formil-peptídeo 2/receptor lipoxina a4 (fpr2/alx) para tratamento de doença cardíaca | |
| BR112015017909A2 (pt) | redução do risco de doença autoimune | |
| ES2721159T3 (es) | Antígenos asociados a tumor independientes de MHC novedosos | |
| PE20141826A1 (es) | Uso de composiciones nutricionales que incluyen lactoferrina en apoyo a la resistencia a enfermedades y condiciones | |
| BR112015001885A2 (pt) | super agonistas de ação longa de hormônio glicoproteína |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |